Current Challenges and New Opportunities in Follicular Lymphoma

STATEMENT OF NEED

Of the estimated 74,680 new cases of non-Hodgkin lymphoma each year in the United States, approximately 35% are follicular lymphoma (FL), an indolent, difficult-to-treat B-cell malignancy. Most patients are diagnosed at an average age of 65 years. Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment and evolving disease subtypes continue to hamper patient outcomes, and multiple recurrences with available therapies are common. Currently, allogeneic hematopoietic stem cell transplant is the only curative therapeutic modality for relapsed/refractory disease. However, the risk for comorbidities and secondary cancers limit the utility of this treatment upfront. Further research is required to determine the optimal timing and role of transplant and novel therapies to keep the remission rate among FL patients high and durable.

TARGET AUDIENCE

Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with FL.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Evaluate predictive and prognostic markers that can inform personalized care plans for patients with FL
Assess emerging efficacy and safety data on novel therapies for previously untreated and relapsed/refractory FL
Apply strategies to control treatment-related adverse events in patients with FL